Work Area: Licensing

Latest content

CRISPR FTO complexities not going anywhere in wake of Broad Institute victory, says IP chief on the CVC side

Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech

04 April 2022

Five key takeaways from IPBC Europe

Returning from two action-packed days in London, IAM Deputy Editor Adam Houldsworth reflects on the surprising state of corporate UPC strategies, the rise of AI, FRAND fireworks and more

02 April 2022

BlackBerry patent sale clears regulatory review, but buyer still has financing details to iron out

Catapult IP Innovations is using a $450 million loan to purchase the 38,000 patents, but 90% of the debt commitment is conditional upon its success in raising $90 million in equity financing by April’s end

01 April 2022

Japan ministry publishes FRAND patent licensing guidelines

The advisory document lays out acceptable behaviours at four stages of the SEP negotiation process

01 April 2022

Highlights from the final day of IPBC Europe 2022

Patent value, IP finance and the challenges of digitisation were just some of the subjects discussed in front of a sell-out audience in London yesterday

31 March 2022

A fairer way to determine royalties in Turkish compulsory licensing

If compulsory licensing is used in Turkey, it is imperative that the individual requirements of each case are considered. This is especially important when it comes to facilitating access to medical treatments for covid-19.

30 March 2022

All the action from Day One of this year's IPBC Europe

A feisty FRAND debate, the UPC and plenty more besides came up for discussion in front of a packed audience of over 280 delegates in London

30 March 2022

IBM’s IP head explains strategy behind the company’s litigation track record

“Take me seriously, because you're going to spend a bunch of money and then decide you need to take a licence,” says Bill LaFontaine, Big Blue’s general manager of intellectual property, in an exclusive IAM interview

29 March 2022

500 million reasons why Ericsson’s patent showdown with Apple matters so much

Huge dollar sums are at stake in the Swedish company’s licensing dispute with the iPhone giant, writes Avikka AB managing director Eric Stasik

29 March 2022

Bristol-Myers Squibb suit against AstraZeneca may boost hefty immuno-oncology IP revenues

Latest fight over anti-PD-L1 antibodies has high financial stakes

29 March 2022

• <
• 1
• ...
• 2
• ...
• 16
• 17
• 18
• 19
• ...
• 20
• 21
• 22
• ...
• >